Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MGTX 
MeiraGTx Holdings PLC (MGTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: MGTX (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $27.5
1 Year Target Price $27.5
| 3 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.93% | Avg. Invested days 30 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 672.66M USD | Price to earnings Ratio - | 1Y Target Price 27.5 |
Price to earnings Ratio - | 1Y Target Price 27.5 | ||
Volume (30-day avg) 5 | Beta 1.18 | 52 Weeks Range 3.85 - 8.75 | Updated Date 07/9/2025 |
52 Weeks Range 3.85 - 8.75 | Updated Date 07/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.31 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2159.71% |
Management Effectiveness
Return on Assets (TTM) -37.28% | Return on Equity (TTM) -216.14% |
Valuation
Trailing PE - | Forward PE 1.61 | Enterprise Value 687013054 | Price to Sales(TTM) 19.49 |
Enterprise Value 687013054 | Price to Sales(TTM) 19.49 | ||
Enterprise Value to Revenue 19.91 | Enterprise Value to EBITDA -3.29 | Shares Outstanding 80365400 | Shares Floating 36569453 |
Shares Outstanding 80365400 | Shares Floating 36569453 | ||
Percent Insiders 24.27 | Percent Institutions 60.04 |
Upturn AI SWOT
MeiraGTx Holdings PLC
Company Overview
History and Background
MeiraGTx Holdings PLC is a clinical-stage gene therapy company founded in 2015. They focus on developing novel gene therapies for serious diseases. The company has collaborations with various academic and industry partners to advance its pipeline.
Core Business Areas
- Gene Therapy Development: MeiraGTx focuses on developing and manufacturing gene therapies for a range of diseases.
- Ophthalmology: Developing gene therapies for inherited retinal diseases.
- Salivary Gland Diseases: Developing gene therapies for radiation-induced xerostomia.
- Neurodegenerative Diseases: Developing gene therapies for neurological disorders.
Leadership and Structure
Alexandria Forbes serves as the President and CEO. The company operates with a focus on research and development, clinical trials, and manufacturing.
Top Products and Market Share
Key Offerings
- AAV2-hAQP1: Gene therapy for radiation-induced xerostomia. Market share information is not publicly available at this early stage of drug development. Competitors include companies developing supportive care treatments for xerostomia.
- Botaretigene Sparoparvovec (AAV2-RPGR): Gene therapy candidate for X-linked retinitis pigmentosa (XLRP). Market share unavailable as it's still in development. Competitors include other companies pursuing gene therapies for XLRP.
Market Dynamics
Industry Overview
The gene therapy industry is rapidly growing, with advancements in technology and increasing regulatory approvals. It's characterized by high R&D costs, long development timelines, and significant potential for treating genetic diseases.
Positioning
MeiraGTx is positioned as a specialized gene therapy company with a focus on ophthalmology, salivary gland diseases, and neurodegenerative disorders. Competitive advantages include proprietary technologies and collaborations.
Total Addressable Market (TAM)
The total addressable market for gene therapies is estimated to reach billions of dollars. MeiraGTx is targeting specific rare disease markets, allowing it to address niche segments within the broader gene therapy market. The exact TAM for their target indications is evolving based on clinical advancements and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Strong IP portfolio
- Experienced management team
- Proprietary manufacturing capabilities
- Strategic collaborations
Weaknesses
- Limited commercialized products
- High R&D expenses
- Dependence on clinical trial outcomes
- Relatively small market capitalization
Opportunities
- Expansion of pipeline through strategic partnerships
- Regulatory approvals for key product candidates
- Technological advancements in gene therapy
- Increased investment in gene therapy research
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from larger pharmaceutical companies
- Patent challenges
Competitors and Market Share
Key Competitors
- SPHR
- VRTX
- BLUE
Competitive Landscape
MeiraGTx operates in a competitive landscape with both established pharmaceutical companies and emerging biotech firms focused on gene therapy. Advantages include its specialized focus and proprietary technology, while disadvantages include its smaller size and limited resources compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: MeiraGTx has shown revenue growth primarily through collaboration agreements and milestone payments.
Future Projections: Future growth is dependent on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary based on pipeline progress.
Recent Initiatives: Recent initiatives include advancing clinical trials for key product candidates and expanding manufacturing capabilities.
Summary
MeiraGTx is a clinical-stage gene therapy company with a promising pipeline, but it's also operating with substantial losses due to high R&D costs. Revenue is growing through partnerships, but success hinges on positive clinical trial results and regulatory approvals. The company needs to effectively manage its cash flow and navigate the competitive gene therapy landscape to realize its full potential. Their pipeline and focus on genetic diseases holds strong promise.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Data may be subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MeiraGTx Holdings PLC
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2018-06-08 | CEO, President & Director Dr. Alexandria Forbes Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 372 | Website https://meiragtx.com |
Full time employees 372 | Website https://meiragtx.com | ||
MeiraGTx Holdings plc, a clinical stage genetics medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also developing AAV-AQP1 in Phase 2 trial for radiation-induced grade 2/3 radiation-induced xerostomia, as well as in Phase ½ trial for Sjogren's syndrome; AAV-GAD in Phase 2 trial for Parkinson's disease; AAV-RPE65 in Phase 2 trial for RPE65-associated retinal dystrophy; and AAV-CNGB3 and AAV-CNGA3, which are both in Phase 2 trial for achromatopsia, as well as offers AAV-AIPL1 for Leber congenital amaurosis (LCA) 4. In addition, the company's products under preclinical development include AAV-RDH12 for retinol dehydrogenase 12 mutation-associated retinal dystrophy; AAV-BBS10 for Bardet-Biedl syndrome (BBS) due to BBS10 mutations; AAV-RetGC for LCA type 1; and AAV-UPF1 for amyotrophic lateral sclerosis, as well as programs for Alzheimer's disease, and wet and dry neovascular age related macular degeneration. Further, it provides riboswitch platform for the delivery of metabolic peptides; and cell therapies for oncology, autoimmune disease, and long term intractable pain. The company has collaborations with Johnson & Johnson Innovative Medicine for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease; and Hologen Limited for the research, development, manufacture, and commercialization of AAV-GAD investigational gene therapy for the treatment of Parkinson's disease, AAV-BDNF investigational gene therapy for genetic obesity disorders, and other genetic medicines to the central nervous system. MeiraGTx Holdings plc was founded in 2015 and is based in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.